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Abstract
Aims/hypothesis The aim of this work was to investigate whether different clinical pain phenotypes of diabetic polyneuropathy
(DPN) are distinguished by functional connectivity at rest.
Methods This was an observational, cohort study of 43 individuals with painful DPN, divided into irritable (IR, n = 10) and non-
irritable (NIR, n = 33) nociceptor phenotypes using the German Research Network of Neuropathic Pain quantitative sensory
testing protocol. In-situ brain MRI included 3D T1-weighted anatomical and 6 min resting-state functional MRI scans. Subgroup
differences in resting-state functional connectivity in brain regions involved with somatic (thalamus, primary somatosensory
cortex, motor cortex) and non-somatic (insular and anterior cingulate cortices) pain processing were examined. Multidimensional
reduction of MRI datasets was performed using a machine-learning approach to classify individuals into each clinical pain
phenotype.
Results Individuals with the IR nociceptor phenotype had significantly greater thalamic–insular cortex (p false discovery rate
[FDR] = 0.03) and reduced thalamus–somatosensory cortex functional connectivity (p-FDR = 0.03). We observed a double
dissociation such that self-reported neuropathic pain score was more associated with greater thalamus–insular cortex functional
connectivity (r = 0.41; p = 0.01) whereas more severe nerve function deficits were more related to lower thalamus–
somatosensory cortex functional connectivity (r = −0.35; p = 0.03). Machine-learning group classification performance to iden-
tify individuals with the NIR nociceptor phenotype achieved an accuracy of 0.92 (95% CI 0.08) and sensitivity of 90%.
Conclusions/interpretation This study demonstrates differences in functional connectivity in nociceptive processing brain
regions between IR and NIR phenotypes in painful DPN. We also establish proof of concept for the utility of multimodal
MRI as a biomarker for painful DPN by using a machine-learning approach to classify individuals into sensory phenotypes.
Keywords Diabetic neuropathy .Machine learning .MRI . Painful diabetic neuropathy . Resting-state functionalMRI
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Painful distal symmetrical peripheral neuropathy is highly
prevalent in individuals with diabetes and is often refractory,
causing substantial disability and deterioration in quality of
life. Pharmacotherapy is the mainstay of treatment but the best
we can hope for is 50% pain relief in only one-third of patients
[1]. This wide variability in treatment response may in part be
due to an underlying heterogeneity in clinical pain phenotypes
[2]. Using quantitative sensory assessments, individuals with
painful diabetic polyneuropathy (DPN) can be broadly
subdivided into two phenotypes: irritable (IR), presenting as
sensate or relatively preserved sensory function associated
with thermal and/or mechanical hyperalgesia; and non-
irritable (NIR), presenting as insensate (i.e. dominated by ther-
mal and mechanical sensory loss) [3]. Subsequent studies
suggest that some treatments are more effective in patients
with the IR compared with the NIR nociceptor phenotype
[4]. Consequently, pain phenotyping may become important
in guiding individual patients’ treatment, although the exact
approach is heavily debated.
Resting-state functional MRI (RS-fMRI) is a quick, non-
invasive technique for examining brain function during rest-
ing conditions. It utilises spontaneous fluctuations in blood
oxygen level-dependent (BOLD) signal to identify brain areas
of increased or decreased neuronal activity while the individ-
ual lies quietly. The analysis involves identification of
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correlations in BOLD signal between remote brain areas,
referred to as functional connectivity [5]. This recent advance
offers huge promise for improving the clinical applicability of
functional MRI.
We have previously reported structural and functional
central nervous system alterations in individuals with ‘painful
hypoaesthesia’ [6] or the painful/painless diabetic foot, which
is most closely related to the NIR phenotype. We have also
demonstrated how central nervous system changes relate to
treatment response in painful DPN [7]. Hence, we hypothesise
that in individuals who have painful DPN, alterations in
somatosensory network functional connectivity differentiate
those with the IR phenotype from those with the NIR pheno-
type. The primary aim of this study was to examine RS-fMRI
functional connectivity in individuals who have painful DPN
with the IR and the NIR phenotype. Our secondary aim was to
demonstrate ‘proof of concept’ that machine-learning
approaches can be used on neuroimaging datasets to classify
individuals with painful DPN into sensory phenotypes. If
successful, this would provide an alternative, objective, novel
method for assessing an individual’s pain phenotype.
Methods
Study population Forty-three, right-handed individuals with
painful DPN, aged 18–65 years, with pain duration for at least
6 months, were consecutively recruited from attendees at
Sheffield Teaching Hospital NHS Trust painful DPN clinics.
Individuals with concurrent severe psychiatric disorders,
moderate-to-severe pain from other causes, non-diabetic
neuropathies, epilepsy, recurrent severe hypoglycaemia and
other factors that would preclude MRI were excluded. The
Institutional Review Board of the Sheffield Research Ethics
Committee approved the study. All participants provided writ-
ten informed consent for study participation.
Definition of painful DPN Painful DPNwas defined as a combi-
nation of neuropathic symptoms (Neuropathy Total Symptom
Score-6 [NTSS-6]) [8] and signs (Toronto Clinical Neuropathy
Score [TCNS] >5) [9], and was confirmed by abnormalities
noted in nerve conduction studies (see electronic supplementary
material [ESM] Methods) using the American Academy of
Neurology and American Association of Electrodiagnostic
Medicine recommendations for the minimum case definition
criterion for confirmation of DPN [10]. There were 16 sural
nerve (2 IR and 14 NIR) and 16 peroneal nerve conduction
responses (2 IR and 14 NIR) that were not recordable. The
NTSS-6 evaluates the frequency and intensity of individual
neuropathy sensory symptoms identified frequently by those
with DPN: numbness and/or insensitivity; prickling and/or
tingling sensation; burning sensation; aching pain and/or tight-
ness; sharp, shooting, lancinating pain; and allodynia and/or
hyperalgesia [8]. The TCNS is a screening tool for DPN and
correlates with DPN severity. It uses a simplified neurological
examination to assess peripheral sensory perception and the pres-
ence of neuropathy symptoms [9].
Sensory phenotyping and quantitative sensory assessments
Quantitative sensory testing (QST) is a means of assessing
sensory phenotype and differences in QST variables may give
insight into pathophysiological mechanisms. All participants
with painful DPN underwent QST of the feet using the proto-
col developed by the German Research Network of
Neuropathic Pain (DFNS) [11]. GS,MA and FH-G underwent
formal training in conducting the DFNS QST protocol at
Mannheim University using healthy volunteers. The QST
results were used to classify participants into IR and NIR
nociceptor phenotypes. Cold and warm detection thresholds,
as well as cold and heat pain thresholds and thermal sensory
limens (including paradoxical heat sensations), were
established using a MEDOC TSA-II Neurosensory Analyser
(Ramat Yishai, Israel). We also tested mechanical detection
and pain thresholds and mechanical pain sensitivity,
allodynia, pressure pain thresholds (PPTs), wind-up ratio
(WUR) and vibration detection thresholds. The mechanical
detection threshold was assessed with a set of standardised
von Frey filaments (0.25, 0.5, 1, 2, 4, 8, 16, 32, 64, 128 and
256 mN; Nervtest, Marstock, Germany) using a modified
method of limits. The mechanical pain threshold was assessed
with a set of seven metal probes of standardised stimulus
intensities (8, 16, 32, 64, 128, 256 and 512 mN; MRC
Systems – Medizintechnische Systeme, Heidelberg,
Germany), using a uniform skin contact area of 0.25 mm
and a modified method of limits. The mechanical pain sensi-
tivity of the skin and dynamic mechanical allodynia were
determined using the same set of seven metal probes with
standardised stimulus intensities and, in addition, a set of
seven light intensity stimuli: a cotton wool ball with a force
of 3 mN; a Q-tip (fixed to a plastic stick) with a force of 100
mN; and a paintbrush with an applied force of 200–400 mN.
These stimuli were applied 50 times (five runs of ten stimuli
per test site in different pseudo-randomised sequence), and the
participants were asked to rate the intensity of each stimulus
on a 0–100 numeric rating scale (0, no pain; 100, most severe
pain). The WUR, as a measure of enhanced temporal summa-
tion, was examined by a pinprick stimulus of standardised
intensity (256 mN). The stimulus was first applied singularly
and then in a series of ten stimuli with a frequency of 1 Hz
within an area of 1 cm2. Participants were asked to rate the
intensity of the first stimulus and the mean of ten stimuli on a
scale of 0–100. The ratio between the two measures was
calculated as WUR; a WUR of >1 indicates enhanced tempo-
ral summation. The vibration detection threshold was exam-
ined using a tuning fork (64 Hz, 8/8 scale) at the (lateral or
medial) malleolus area. Muscular pressure pain threshold was
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examined by applying mechanical pressure at a rate of 0.5 kg/s
(Algometer, Somedic, Sweden) at the abductor halluces
muscle. Except for the vibration detection threshold and pres-
sure pain threshold, all sensory tests were performed in the S1
dermatome bilaterally (unless defined by the distribution of
symptoms). Participants were familiarised with the testing
procedure on the dorsum of the forearm before all variables
were measured over the dorsum of both feet (S1 dermatome).
PPTs were recorded over the arch of the foot and vibration
detection thresholds were tested over the medial malleolus.
The QST data were entered into the data analysis system
eQUISTA provided by the DFNS. eQUISTA transformed the
rawQST data into z scores thus normalising for age, sex and the
body location of testing [12]. Positive z scores denote gain of
function, whereas negative z scores denote loss of function.
Based on quantitative sensory assessment findings, participants
were divided into IR nociceptor phenotype (defined as the pres-
ence of either dynamic mechanical allodynia, reduced mechan-
ical or pressure threshold, increased mechanical pain sensitivi-
ty, or lower cold or heat pain threshold, or any combination of
these signs of hyperexcitability) or NIR nociceptor phenotype
(participants not classified as IR nociceptor phenotype [i.e.
sensory loss with no signs of hyperexcitability]) using recom-
mendations previously described [13].
MRI acquisition and analyses Anatomical data were acquired
using a T1-weighted magnetisation prepared rapid acquisition
gradient echo sequence (repetition time [TR] 7.2 ms, echo
time [TE] 3.2 ms, flip angle 8° and voxel size 0.9 mm3, yield-
ing isotropic spatial resolution). A 6 min resting-state fMRI
sequence was acquired while participants fixated on a cross
using a T2*-weighted pulse sequence (TE 35 ms; TR
2600ms, in-plane pixel dimensions 1.8 mm× 1.8 mm, contig-
uous trans-axial slices 4 mm thick). MRI was performed at
3.0 T (Ingenia; Phillips Medical Systems, Best, Holland).
Ten regions of interest (ROIs) involved in somatic and
non-somatic pain processing were chosen for analyses: bilat-
eral primary somatosensory cortex (S1), motor cortex (M1),
insular cortex, anterior cingulate gyrus and thalamus. RS-
fMRI analysis was performed using the NITRC Functional
Connectivity (CONN) Toolbox 18.b (www.nitrc.org/
projects/conn) [14] and SPM8 (Wellcome Trust Centre for
Neuroimaging London, UK) in Matlab 2019a (the
MathWorks, Natick, MA, USA). Functional connectivity
matrices between the pre-specified ROIs were calculated and
the IR vs NIR nociceptor phenotype interaction was exam-
ined. The significance of ROI-to-ROI connection was deter-
mined through false-positive control false discovery rate
(FDR)-corrected p values with a χ2 test with two-sided infer-
ences [14]. Cortical reconstruction and volumetric segmenta-
tion were performed with FreeSurfer software (http://surfer.
nmr.mgh.harvard.edu) to obtain anthropometric measures for
each of the ROIs. These results were used to adjust for
regional morphological differences in the resting-state func-
tional connectivity analyses.
Machine-learning methodsWe classified participants with the
IR and NIR nociceptor phenotypes using a hyperparameter
tuned support vector machine (SVM) classifier. Of the 55 total
participant labels used, 14 participants (0.25 testing set) were
used to train and the rest to test our classifier performance. The
ten sources chosen a priori were as described in the resting-
state processing step. These sources were also the features
extracted from the structural and volumetric analysis. Of
these, the most relevant features from both the resting-state
and the T1 image analysis were chosen using a cross-
validated recursive feature elimination method. Lastly, a
tenfold cross-validation was implemented to reduce out of
sample bias. All our analyses were performed using the
Scikit-learn package in Python version-0-22-0 (https://
github.com/scikit-learn/scikit-learn) [15]. The performance
of the machine-learning algorithm to classify participants with
the NIR nociceptor phenotype was determined by the area
under the receiver-operating-characteristic curve, accuracy
and F1 scores. Our classifier was also optimised and the
following hyperparameter tuning values were used in our
SVM classifier.
& Regularisation parameter: C = 100 chosen as imbalanced
datasets benefits from a higher C value [16]
& L2 penalty: we chose L2 as a conventional approach to
regularisation [17]
& Early gradient descent stop at 1 × 10−4: this default value
was chosen to optimise speed
& No class weights: this is the default parameter
& Radial basis function kernel: this was easy to calibrate, is a
non-parametric model enabling better model selection,
and has been shown to perform better than linear and
polynomial kernels [18].
Statistical analysis A p value of < 0.05 was considered statis-
tically significant. Categorical variables were expressed as
numbers and percentages and were compared using Fisher’s
exact or ordinal χ2 tests as appropriate. Continuous variables
were expressed as medians and IQRs or as means and SDs, as
appropriate, and were compared using Student’s t tests (SPSS
Statistics forWindows, version 26.0; IBM, Armonk, USA). In
addition, z values of functional connectivity that were signif-
icantly correlated to severity of neuropathy (TCNS) and pain
scores (NTSS-6) were determined using Pearson correlation
for normally distributed data and Spearman Rank correlation
for non-normally distributed data. The z score was chosen as it
is assumed to be more appropriate than the magnitude of
difference because it also considers the variance in the signal.
Finally, we statistically compared the partial correlation
Diabetologia
Table 1 Clinical and neurophys-








Age, years 56.9 (12.9) 58.4 (11.2) 0.74
Male sex, n (%) 9 (90.0) 20 (60.6) 0.08
Type of diabetes, n type 1/n type 2 3/7 10/23 0.65
Duration of diabetes, years 17.2 (9.5) 18.4 (13.1) 0.78
Duration of pain, years 8.9 (5.6) 8.3 (7.0) 0.80
HbA1c, mmol/mol 69.1 (17.6) 67.6 (15.0) 0.79
HbA1c, % 8.5 (3.8) 8.3 (3.5)
NTSS-6 score 16.5 (3.0) 13.1 (5.0) 0.02
TCNS 19.7 (4.6) 16.1 (9.0) 0.26
Medications, n (%)
Pregabalin/gabapentin 7 (70.0) 14 (42.4) 0.12
Duloxetine 6 (60.0) 10 (30.3) 0.14
Amitriptyline 0 (0) 5 (15.2) 0.32
Opiates 5 (50.0) 11 (33.3) 0.46
Other 0 (0) 2 (6.1) 0.59
Sural nervea
Conduction velocity, m/s 34.2 (9.7) 39.0 (8.1) 0.30
Amplitude, mAmp 3.8 (5.7) 2.9 (6.7) 0.73
Common peroneal nerveb
Conduction velocity, m/s 37.6 (5.0) 35.4 (6.1) 0.41
Amplitude, mAmp 4.7 (2.0) 4.4 (4.2) 0.87
Distal latency (ms) 3.6 (2.4) 1.4 (1.3) 0.007
DFNS QST (z scores)
Cold detection threshold −2.64 (0.6) −2.24 (1.1) 0.28
Warm detection threshold −1.83 (0.3) −1.87 (0.5) 0.79
Thermal sensory limens −2.20 (0.6) −2.13 (0.7) 0.80
Cold pain threshold −1.00 (0.1) −0.73 (0.6) 0.05
Heat pain threshold −1.46 (0.3) −1.38 (0.5) 0.61
PPT 1.80 (1.6) −0.83 (2.2) 0.05
Mechanical pain threshold −1.43 (1.6) −1.71 (1.6) 0.65
Mechanical pain sensitivity 1.07 (2.1) −1.00 (1.6) 0.003
WUR 1.03 (2.2) 0.03 (1.3) 0.12
Mechanical detection threshold −3.35 (1.3) −3.20 (1.6) 0.92
Vibration detection threshold −2.66 (2.4) −3.41 (2.3) 0.39
Brain morphometry
Somatosensory cortex
Surface area, mm2 578.2 (64.3) 535.3 (54.1) 0.04
Verticesc 988.7 (96.1) 913.4 (115.1) 0.05
Volume, mm3 1481.9 (186.2) 1424.7 (185.8) 0.39
Thalamus
Right volume, mm3 6475.0 (701.3) 5874.4 (626.3) 0.01
Left volume, mm3 7327.0 (894.6) 7039.5 (1145.7) 0.47
Anterior cingulate cortex
Thickness, mm 2.38 (0.2) 2.57 (0.2) 0.02
Volume, mm3 1773.5 (390.1) 1773.5 (321.7) 0.99
Verticesc 1032.1 (236.1) 982.7 (165.2) 0.46
Motor cortex
Surface area, mm2 4719.8 (606.6) 4535.9 (413.6) 0.28
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coefficients using the Steiger z transform test [19] implement-
ed on the web version (https://blogs.gwu.edu/weissba/
teaching/calculators/hotellings-t-and-steigers-z-tests/).
Results
Forty-three participants (10 IR nociceptor phenotype, 33 NIR
nociceptor phenotype) completed the study. There was no
significant difference in age, duration or type of diabetes, or
duration of pain or type of pain medication between study
groups (Table 1). Participants with the IR nociceptor pheno-
type (vs NIR nociceptor phenotype) had reduced cold pain
threshold (p=0.05) and greater mechanical pain sensitivity
and PPT (p < 0.05, ESM Fig. 1). A significantly higher
proportion of participants with the IR nociceptor phenotype
displayed dynamic mechanical allodynia (χ2 26.0; p < 0.001)
and paradoxical heat sensation (χ2 10.9; p = 0.001) when
compared with participants with the NIR nociceptor
phenotype.
RS-fMRI data was unavailable for three participants (IR 1,
NIR 2). In participants with the IR nociceptor phenotype,
there was significantly greater resting functional connectivity
between the thalamus and insular cortex (Fig. 1b; β = 0.2,
T(38) = 3.11; p-FDR = 0.03) when compared with partici-
pants with the NIR nociceptor phenotype. Conversely, there
was an opposing pattern for thalamus–somatosensory cortex
functional connectivity; participants with the IR nociceptor
phenotype displayed decreased functional connectivity
compared with those having the NIR nociceptor phenotype
(Fig. 1d; β = −0.22, T(38) = −4.98, p-FDR = 0.03). There
were no significant group differences in functional connectiv-
ity between the other ROIs examined.
Given the relatively low correlation between self-reported
pain and neuropathy severity scores (r = −0.03, p = 0.85), we
investigated whether these measures were associated with
different patterns of thalamic resting-state functional connec-
tivity. Specifically, we tested the double dissociation such that
NTSS-6 pain scores were more associated with thalamus–
insular cortex functional connectivity, while the TCNS scores
were more associated with thalamus–somatosensory cortex
functional connectivity. We observed two significant partial
correlations: one linking NTSS-6 pain scores to thalamus–
insular cortex functional connectivity (Fig. 1e,g, bar 1; r =
0.41; p = 0.01) and the other linking TCNS to thalamus–
somatosensory cortex functional connectivity (Fig. 1f,g, bar
4; r = −0.35; p = 0.03). These results indicate that individuals
with greater thalamus–insular cortex functional connectivity
exhibit higher self-reported pain scores (in keeping with the
IR nociceptor phenotype group having significantly greater
NTSS-6 score than the NIR phenotype group; Table 1, p =
0.02), while individuals with lower functional connectivity of
the thalamus–somatosensory cortex have a larger neuropathy
deficit. By contrast, the partial correlations between NTSS-6
and thalamus–somatosensory cortex functional connectivity
(Fig. 1g, bar 2) and between TCNS and thalamus–insular
cortex functional connectivity (Fig. 1g, bar 3) were not signif-
icant. Of note, the Steiger z transform test revealed that the
magnitude of the partial r encompassing the NTSS-6 score
was significantly greater for thalamus–insula cortex than for
thalamus–somatosensory cortex functional connectivity (Fig.
1g, bar 1 vs bar 2; two-tailed Steiger z test, z = 2.07, p = 0.04).
By contrast, the magnitude of the partial r encompassing the
TCNS score was significantly larger for thalamus–
somatosensory cortex than for thalamus–insula cortex (Fig.
1g, bar 3 vs bar 4; two-tailed Steiger z test, z = 2.02, p =
0.04). These analyses revealed a double dissociation
connecting self-reported pain scores selectively and preferen-
tially to the functional connectivity of the thalamus–insular
cortex within the right hemisphere. By contrast, neuropathy
deficit was related to the reduction in the functional connec-








Verticesc 7347.2 (935.5) 7094.8 (746.0) 0.38
Volume 11,562.3 (1410.4) 11,167.7 (1218.5) 0.39
Insular cortex
Thickness, mm 2.87 (0.2) 2.80 (0.1) 0.27
Volume, mm3 6056.6 (965.9) 6016.3 (677.7) 0.88
Verticesc 3167.3 (428.1) 3182.6 (357.5) 0.91
Data are shown as mean (SD), except where they are reported as n (%)
aTwenty-three (NIR 19, IR 4) sural nerve conduction responses were not recordable
bTwelve (NIR 11, IR 1) peroneal nerve conduction responses were not recordable
c Structural measure vertices are expressed as an arbitrary unit of measurement
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Next , we examined whe the r the func t iona l
connectivity–neuropathy scores dissociation was driven
by structural changes in the thalamus, insular cortex or
somatosensory cortex (Table 1). We repeated the partial
correlation analysis but we also regressed out the
volumes measurements of each of these brain regions.
Once again, the partial correlations linking self-reported
pain scores (NTSS-6) to the thalamus–insular cortex
functional connectivity (r = 0.37, p = 0.03) and linking
neuropathy severity (TCNS) to thalamus–somatosensory
cortex functional connectivity (r = 0.35, p = 0.03) were
demonstrated. Hence, structural changes to the thalamus,
insular cortex and somatosensory cortex do not account
for the functional connectivity–neuropathy score double
dissociation.
Finally, group classification performance of the machine-
learning model for the NIR phenotype achieved an accuracy
of 0.92 (95% CI 0.08) and sensitivity of 90%. The positive
predictive value (NIR) and negative predictive value (IR) was
100% and 67%, respectively. AUC analysis indicated that the
machine-learning model exhibited good performance
accuracy.
Fig. 1 (a–d) Right view of resting-state functional connectivity in indi-
viduals with painful DPN who had the IR nociceptor phenotype (a) and
NIR nociceptor phenotype (c); R, right; IC, insular cortex (Montreal
Neurological Institute [MNI] coordinates: 44, 4, 0); Post CG, postcentral
gyrus (MNI coordinates: 2, −36, 62); Thal, thalamus (MNI coordinates:
10, −19, 6). Bar charts show the effect size of differences in mean thala-
mus–insular cortex (b) and thalamus–postcentral cortex (d) functional
connectivity between study groups (error bars represent 95% CI). (e, f)
Scatter-plots depicting linear correlation between the right thalamus–
insular cortex functional connectivity (R Thal-IC FC) and the NTSS-6
pain scores (e) and between the right thalamus–somatosensory cortex
functional connectivity (R Thal-Post CG FC) and the TCNS (f). (g) Bar
graph plotting four functional connectivity and behaviour partial correla-
tion coefficients (Pearson’s r) derived from the functional connectivity of
the right thalamus–insular cortex (R Thal-IC FC, white bars) and the right
thalamus–somatosensory cortex (R Thal-Post CG FC, black bars). Bars 1
and 2 indicate correlations involving the NTSS-6 and bars 3 and 4 indi-
cate correlations involving the TCNS. Each partial r (e.g. bar 1) is obtain-
ed by correlating a given behaviour (e.g. self-reported pain scores, NTSS-
6) with the functional connectivity derived from a given network (e.g.
right Thal-IC FC). *p<0.05
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Discussion
The key findings from this study were that individuals with
the IR nociceptor phenotype have significantly greater
thalamus–insular cortex functional connectivity and
decreased thalamus–somatosensory cortex functional connec-
tivity compared with those with the NIR nociceptor pheno-
type. Indeed, there was a significant positive correlation
between thalamus–insular cortex functional connectivity and
pain scores (NTSS-6). Similar associations between insular
cortex functional connectivity and pain scores have also been
demonstrated across other chronic pain conditions [20]. Thus,
the insular cortex, which plays a pivotal role in affective and
attentional pain processing [21], may be an overactive pain-
promoting brain region in individuals with the IR nociceptor
phenotype. In addition, there was a greater reduction in
thalamus–somatosensory cortex functional connectivity in
individuals with more severe neuropathy (TCNS). This
suggests that the deafferentation or dying-back axonopathy,
resulting from a severe neuropathy, lead to reduced peripheral
sensory input which in turn leads to a reduction in somatosen-
sory cortical volume [6] and functional connectivity.
Crucially, we observed a double disassociation such that defi-
cits of nerve function were more correlated with thalamus–
somatosensory cortex functional connectivity and self-
reported pain scores were more correlated with thalamus–
insular cortex functional connectivity. Taken together, we
have demonstrated how MRI measures of functional connec-
tivity relate to both the somatic (i.e. TCNS) and non-somatic
(self-reported pain intensity ratings) assessment of painful
DPN. To the best of our knowledge, this is the first time this
has been demonstrated in painful DPN. Future prospective
studies are required to determine the natural history of the
alterations in functional connectivity described in relation to
the onset of painful DPN.
Current therapies for painful DPN have limited efficacy,
as reflected in the high psychosocial burden, low rates of
functional recovery and return to work, and continued
reliance on opioid analgesics [1, 22, 23]. The lack of a
reliable biomarker to stratify patients and to predict thera-
peutic response is one of the main barriers preventing the
identification and development of safe and effective, non-
additive pain medications. We have demonstrated how
structural and functional changes within the central
nervous system reflect an individual’s clinical pain pheno-
type [6] and also predict response to neuropathic pain
treatment [7]. There is now increasing evidence that
magnetic resonance neuroimaging could serve as a reliable
biomarker in clinical trials of pain therapeutics. This could
increase the probability of novel compounds advancing to
Phase II trials, reduce the variability of the therapeutic
response and reduce the overall expense and time of drug
development.
We used machine-learning approaches to integrate MRI
anatomical data and resting-state functional connectivity data
to classify individuals with painful DPN into sensory pheno-
types. We found this approach is feasible with a good degree
of accuracy and performance. Although these findings are
promising, more research is now needed to externally validate
our machine-learning model with a larger sample size. If
successfully validated, multidimensional reduction ofmagnet-
ic resonance neuroimaging data through machine-learning
offers a novel approach to classify patients with painful
DPN into sensory phenotypes.
This study has some limitations, including a study population
with a male predominance and a long pain duration. To assess
this further, we completed a sensitivity analysis by examining
differences in functional connectivity between sexes (male vs
female) and between individuals with long (>8 years) vs short
(<8 years) duration of pain (mean duration of pain in the whole
study population was 8.5 [SD 6.9] years). We found no signifi-
cant differences in functional connectivity in these two compar-
isons. Nevertheless, further studies are required to determine
whether the findings in this study are reproducible across sexes
and individuals with different pain durations. Another limitation
was the lack of a painless DPN control group. This would have
enabled us to determine the differential impact of neuropathy vs
the presence of pain. However, our study findings provide clues
to address this limitation. There was a clear disassociation
between deficits of nerve function that correlated with
thalamus–somatosensory cortex functional connectivity and
self-reported pain scores, which were more correlated with the
thalamus–insular cortex functional connectivity. Future studies
should consider the inclusion of individualswith painlessDPN to
explore this further.
In summary, there has been considerable progress towards a
mechanism-based approach to managing painful DPN in recent
years [24].Much of the focus has been on sensory profiling using
QST, which remains a subjective psychophysical measure.
Crucially, these methods do not capture the complex multiface-
ted experience of pain, which not only affects sensory but also
emotional/cognitive processing. What is clear is that many of the
factors influencing pain perception are centrally mediated and
neuroimaging provides the best tool to quantify this. Using
advanced multimodal magnetic resonance neuroimaging, we
have demonstrated alterations in pain-processing brain regions
that relate to clinical pain phenotype, treatment response [7] and
behavioural/psychological factors impacted by pain [6]. Taken
together, these assessments could serve as a possible central pain
signature for painful DPN. The challenge now, is to apply this
potential pain biomarker at an individual level in order to demon-
strate clinical utility. To this end, we have shown proof of
concept that a machine-learning approach to classify individuals
into different clinical pain phenotypes using brain imaging
features taken from a quick, 6 min RS-fMRI scan is feasible. In
future studies we aim to externally validate and optimise this
Diabetologia
model on a larger cohort of individuals and examinewhether and
how such a model can be used as a biomarker in clinical trials of
pain therapeutics.
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